I have updated the snapshot previously uploaded to Hot Copper for ease of reading and understanding. There is information contained in the below which isn't released in the Lumos provided announcements such as distributors etc as this is publicly sourced information they don't provide. You can happily google the distributors / resellers listed below online to confirm they are still actively selling the product. I hold no responsibility for any market changes to the information below as this is subject to change.
This isn't 100% clear from the company. However notable clients include
Trials: Lumos has a few trials/studies being conducted both company initiated, to support services clients and through other third parties. These include
Aptatek PHK test, Febridx CLIA waiver study (both in the US) and University of Bristol in the UK. They have noted there is an upcoming study/trial out of the
University of Wollongong to be conducted at some stage (Australia).Products: In addition to the noted products in the graphics, Lumos is currently developing / investigating
women's sexual health products to be Lumos branded. I would refer to the most recent announcements for more (Quarterly report released 29th April 2025). Lumos also has distribution rights for
BINX IO System.
Febridx: Current market
without CLIA Waiver: 20,000-30,000 sites (mostly hospital-affiliated or specialized practices). Potential market
with CLIA Waiver: 220,000 sites (e.g. urgent care, GP offices, retail clinics, pharmacies, school clinics).
Hopefully this provides the most recent snapshot of info to start your research and alongside the company announcements, provides further understanding of where the fundamentals of the company are.
